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Translational Relevance 
Although several genetic loci have been identified for ovarian cancer risk, finding loci 
associated with outcome remains a challenge primarily because of treatment heterogeneity 
and small sample sizes. We comprehensively analyzed ~2.8 million variants in the largest 
collection to date of epithelial ovarian cancer cases with detailed chemotherapy and clinical 
follow-up data, and identified SNPs in three long non-coding RNAs (lncRNAs) that were 
associated with progression-free survival, one of which lies within a super-enhancer  recently 
shown to be associated with poor prognosis in another solid tumor.  There is a growing body 
of evidence that lncRNAs are cancer-specific regulators in signalling pathways underlying 
metastasis and disease progression.  While additional work is needed to delineate the role of 
associated SNPs on lncRNA expression and validate their role in a larger sample, our 
findings have important implications for the development of diagnostic markers of 
progression and novel therapeutic targets for epithelial ovarian cancer. 
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Abstract 
Purpose: Chemotherapy resistance remains a major challenge in the treatment of ovarian 
cancer. We hypothesize that germline polymorphisms might be associated with clinical 
outcome.  
Experimental Design: We analyzed ~2.8 million genotyped and imputed SNPs from the 
iCOGS experiment for progression-free survival (PFS) and overall survival (OS) in 2,901 
European epithelial ovarian cancer (EOC) patients who underwent firstline treatment of 
cytoreductive surgery and chemotherapy regardless of regimen, and in a subset of 1,098 
patients treated with ≥4 cycles of paclitaxel and carboplatin at standard doses.  We evaluated 
the top SNPs in 4,434 EOC patients including patients from The Cancer Genome Atlas.  
Additionally we conducted pathway analysis of all intragenic SNPs and tested their 
association with PFS and OS using gene set enrichment analysis.   
Results:  Five SNPs were significantly associated (p≤1.0x10-5) with poorer outcomes in at 
least one of the four analyses, three of which, rs4910232 (11p15.3), rs2549714 (16q23) and 
rs6674079 (1q22) were located in long non-coding RNAs (lncRNAs) RP11-179A10.1, RP11-
314O13.1 and RP11-284F21.8 respectively (p≤7.1x10-6).  ENCODE ChIP-seq data at 1q22 
for normal ovary shows evidence of histone modification around RP11-284F21.8, and 
rs6674079 is perfectly correlated with another SNP within the super-enhancer MEF2D, 
expression levels of which were reportedly associated with prognosis in another solid tumor.  
YAP1- and WWTR1 (TAZ)-stimulated gene expression, and HDL-mediated lipid transport 
pathways were associated with PFS and OS, respectively, in the cohort who had standard 
chemotherapy (pGSEA≤6x10-3). 
Conclusion: We have identified SNPs in three lncRNAs that might be important targets for 
novel EOC therapies.  
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Introduction 
Approximately 238,000 women are diagnosed with ovarian cancer each year. It is the leading 
cause of death from gynecological cancers and globally approximately 152,000 women will 
die annually from the disease (1). Over the past three decades, significant advances have been 
made in chemotherapy for epithelial ovarian cancer (EOC), and the combination of 
cytoreductive surgery followed by the doublet of a taxane (paclitaxel 135 – 175 mg/m2) and 
platinum (carboplatin AUC > 5) repeated every three weeks has been the most common 
regimen for primary treatment of this disease, with initial tumor response rates ranging from 
70-80% (2, 3).  Although survival rates have improved in the past decade, resistance to 
chemotherapy remains a major challenge, and the majority of patients with advanced disease 
succumb to the disease despite initial response to first line treatment (4).  The identification 
of genes relevant to response to chemotherapy and survival of ovarian cancer may contribute 
to a better understanding of prognosis, and potentially guide the selection of treatment 
options to help circumvent this obstacle. 
It is well recognized that genetic variation can have a direct effect on inter-individual 
variation in drug responses, although patient response to medication is dependent on multiple 
factors ranging from patient age, disease type, organ functions, concomitant therapy and drug 
interactions (5).  Comparisons of intra-patient and inter-patient variability in both population-
based and twin studies have demonstrated that the smallest differences in drug metabolism 
and their effects are between monozygotic twins, which is consistent with the hypothesis that 
genetics may play a significant role in drug responses (6, 7).  While many cancer treatments 
have been successful in shrinking or eradicating tumor cells, studies of genetic factors related 
to drug responses are particularly challenging because tumor cell and the non-cancerous host 
tissue from which they arise share the same genetic background, and failure of treatment may 
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be due to the presence of de novo or acquired somatic alterations in tumors rather than 
germline variation (8).   
To date several candidate gene studies have explored germline polymorphisms for an 
association with response to chemotherapy for ovarian cancer (9).  Some obvious candidates 
are genes that encode drug-metabolizing enzymes and drug transporters that can influence 
toxicity or treatment response.  The most clinically relevant drug metabolising enzymes are 
member of the cytochrome P450 (CYP) superfamily, of which CYP1, CYP2, and CYP3 
contribute to the metabolism of more than 90% of clinically used drugs.  There is 
considerable evidence that polymorphisms in the CYP genes have a significant impact on 
drug disposition and response, and >60% of Food and Drug Administration (FDA)-approved 
drug labels regarding genomic biomarkers pertain to polymorphisms in the CYP enzymes 
(10).  Similarly the ABCB1 gene, the most extensively studied ATP-binding cassette (ABC) 
transporter involved in transport of a wide range of anti-cancer drugs including paclitaxel 
(11), was previously shown to be associated with response to first-line paclitaxel-based 
chemotherapy regimens for ovarian cancer (12, 13).  A systematic review of the most 
commonly evaluated genes in gynecologic cancers, including ABCB1, showed inconsistent 
findings across studies (14).  Other studies including a comprehensive study of ABCB1 SNPs 
putatively associated with progression-free survival (PFS) undertaken by the Ovarian Cancer 
Association Consortium (OCAC) did not replicate the association with PFS, although the 
possibility of subtle effects from one SNP on overall survival (OS) could not be discounted 
(13).  Recently several ABCA transporters were explored in expression studies using cell-
based models and shown to be associated with outcome in serous EOC patients (15), 
although this finding would need to be replicated in a larger independent study.   
Research. 
on October 12, 2015. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 7, 2015; DOI: 10.1158/1078-0432.CCR-15-0632 
12 
 
However, inter-individual variation in response to chemotherapy and post-treatment 
outcomes cannot be fully explained by genetic variations in the genes encoding drug 
metabolizing enzymes, transporters, or drug targets.  Recent studies by the OCAC and the 
Australian Ovarian Cancer Study (AOCS) found that EOC patients carrying BRCA1 or 
BRCA2 germline mutations had better response to treatment and better short-term survival (5 
years) than non-carriers (16, 17).  This survival advantage is supported by in vitro studies of 
BRCA1/2 mutated ovarian cancer cell lines that were shown to be more sensitive to platinum-
based chemotherapy (18, 19).  Genome-wide approaches that integrate SNP genotypes, drug-
induced cytotoxicity in cell lines and gene expression data have been proposed as models for 
identifying predictors of treatment outcome (20), although their utility when applied to 
patient data proved inconclusive (21).   
While in vitro studies have suggested functional relevance for genes and associated SNPs, the 
clinical utility of these findings remains in question mainly due to inconsistent results from 
under-powered and heterogeneous patient studies.  In this report we present the findings from 
a comprehensive large-scale analysis of ~2.8 million genotyped and imputed SNPs from the 
Collaborative Oncological Gene-environment Study (COGS) project in relation to 
progression-free and overall survival as surrogate markers of response to chemotherapy in 
~3,000 EOC patients with detailed first-line chemotherapy and follow-up data from the 
OCAC.  In a secondary analysis, we also evaluated the association between OS and ~2.8 
million SNPs in ~11,000 EOC patients irrespective of treatment regimen. 
Materials and methods 
Study Populations 
The main analysis was restricted to invasive EOC patients with detailed chemotherapy and 
clinical follow-up for disease progression and survival following first-line treatment from 
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thirteen OCAC studies in the initial phase, with an additional four OCAC studies and patients 
from The Cancer Genome Atlas (TCGA) included in the validation phase (Supplementary 
Tables 1).  Patients were included if they received a minimum of cytoreductive surgery as 
part of primary treatment, and were of European ancestry, determined using the program 
LAMP (22) to assign intercontinental ancestry based upon a set of unlinked markers also 
used to perform principal component (PC) analysis within each major population subgroup 
(23).  A total of 2,901 patients were eligible for the main analysis, a subset of whom 
(n=1,098) were treated with ≥4 cycles of standard doses of paclitaxel and carboplatin 
intravenously (IV) at 3-weekly intervals. Clinical definitions and criteria for progression 
across studies have been previously described (13).  Data from TCGA 
(http://cancergenome.nih.gov/) was downloaded through the TCGA data portal and assessed 
for ancestral outliers to determine those of European descent.  A secondary analysis of OS in 
~11,000 European EOC patients was also done using patients from 30 OCAC studies 
(Supplementary Table 2). All studies received approval from their respective human research 
ethics committees, and all OCAC participants provided written informed consent.   
Genotyping and imputation 
The Collaborative Oncological Gene-environment Study (COGS) and two ovarian cancer 
GWAS have been described in detail elsewhere (24).  Briefly, 211,155 SNPs were genotyped 
in germline DNA from cases and controls from 43 studies participating in OCAC using a 
custom Illumina Infinium iSelect array (iCOGS) designed to evaluate genetic variants for 
association with risk of breast, ovarian and prostate cancers.  In addition, two new ovarian 
cancer GWAS were included which used Illumina 2.5M and Illumina OmniExpress arrays.  
Genotypes were imputed to the European subset of the phased chromosomes from the 1000 
Genome project (version 3). Approximately 8 million SNPs with a minor allele frequency 
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(MAF) of at least 0.02 and an imputation r2>0.3 were available for analysis, ~2.8 million of 
which were well imputed (imputation r2 ≥0.9) and were retained in survival analyses.  DNA 
extraction, iPLEX genotyping methods and quality assurance for additional samples 
genotyped for the validation analysis have also been previously described (25). 
Statistical Analysis 
The main analyses were the association between ~2.8 million SNPs and progression-free 
survival (PFS) and overall survival (OS).  Analyses of PFS and OS were conducted 
separately for all patients known to have had a minimum of cytoreductive surgery for first-
line treatment regardless of chemotherapy, hereafter referred to as the ‘all chemo’ analysis, 
and in a subset of patients known to have received standard of care first-line treatment of 
cytoreductive surgery and ≥4 cycles of paclitaxel and carboplatin IV at 3-weekly intervals, 
hereafter referred to as the ‘standard chemo’ subgroup (Supplementary Table 1).  The 
majority of patients in the ‘standard chemo’ cohort were known to have had paclitaxel at 175 
or 135 mg/m2 and carboplatin AUC 5 or 6; for the remainder, standard dose was assumed 
based on treatment schedules.  PFS was defined as the interval between the date of 
histological diagnosis and the first confirmed sign of disease progression or death, as 
previously described (13); OS was the interval between the date of histological diagnosis and 
death from any cause.  Patients who had an interval of >12 months between the date of 
histological diagnosis and DNA collection were excluded from the analysis to avoid survival 
bias.  A secondary analysis was OS in the largest available dataset of European invasive EOC 
patients regardless of treatment (n=11,311), hereafter referred to ‘all OCAC’. 
For the main analysis of PFS and OS in ‘all chemo’ and ‘standard chemo’, we obtained the 
per-allele hazard ratio [log(HR)] and standard error for each SNP using Cox regression 
models including study, the first two PCs, residual disease (nil vs. any), tumor stage (FIGO 
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stages I-IV), histology (5 subtypes), tumor grade (low vs. high), and age at diagnosis (OS 
analysis only) as covariates.  To avoid inflation for rare SNPs, the likelihood ratio test was 
used to estimate the standard error for iCOGS SNPs and meta-analyzed with samples 
included in the US GWAS and U19 studies based on expected imputation accuracy for 
imputed SNPs.  For secondary analysis of OS in the ‘all OCAC’ dataset, Cox regression 
models included study, age, and the first two PCs and histology as covariates.  For the US 
GWAS and U19 studies, the principal components were estimated separately and the top two 
and top principal components used respectively. All tests for association were two-tailed and 
performed using in-house software programmed in C++ and STATA SE v. 11 (Stata Corp., 
USA).  Manhattan and QQ plots were generated using the R project for Statistical Computing 
version 3.0.1 (http://www.r-project.org/), and meta-analysis was done using the program 
Metal (26), and between-study heterogeneity was assessed using the likelihood ratio test to 
compare regression models with and without a genotype-by-study interaction term. 
SNP selection for validation  
Preliminary analyses suggested that dosage scores from imputed SNPs with imputation r2 
<0.9 were not representative of actual genotypes in this sample (Supplementary Methods & 
Supplementary Table 3).  We therefore selected SNPs with imputation r2 ≥0.9 and adjusted 
p≤1.0x10-5 in at least one of the four main analyses (PFS and OS in ‘all chemo’ and ‘standard 
chemo’) for genotype validation.  SNPs were binned into LD blocks defined by pairwise 
correlation (r2) > 0.8.  We used Sequenom Assay Designer 4.0 to design two multiplexes in 
order to capture at least one SNP representing each block, although some blocks contained 
SNPs for which an iPLEX assay could not be designed (n=10).  All patients for whom we 
had DNA, clinical follow-up and chemotherapy data were genotyped.  We then meta-
analyzed estimates from the genotyped samples with non-overlapping iCOGS samples and 
Research. 
on October 12, 2015. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 7, 2015; DOI: 10.1158/1078-0432.CCR-15-0632 
16 
 
TCGA data to obtain effect estimates from the largest possible dataset.  SNPs that were 
significant at p≤1.0x10-5 in at least one outcome in the final analysis were queried for 
association with expression of protein-coding genes within 1Mb of the lead SNP using GEO, 
EGA and TCGA expression array data analyzed in KM-plotter (27). 
Pathway analysis 
All intragenic SNPs of the ~8 million (MAF ≥ 0.02 and imputation r2>0.3) with p-values for 
association with PFS and OS in the ‘standard chemo’ cohort were mapped to 25,004 genes 
annotated with hg19 start and end positions. The boundaries of each gene were extended by 
50 kb on both sides for SNP-to-gene mapping to include cis-regulatory variation. A total of 
23,490 genes were captured by at least one SNP. The negative logarithm (base 10) of the p-
value of the most significant SNP in each gene, adjusted for the number of SNPs in the gene 
(±50 kb) by a modification of the Sidak correction (28, 29) was used to rank genes based on 
their association with PFS and OS (‘standard chemo’).  A total of 837 known biological 
pathways (containing between 15 to 500 genes each) from the Kyoto Encyclopedia of Genes 
and Genomes (KEGG), BioCarta, and Reactome, three standard expert-curated pathway 
repositories, were accessed via the Molecular Signatures Database (version 4.0; 
http://www.broadinstitute.org/gsea/msigdb). The pathways were tested for their association 
with PFS and OS using gene set enrichment analysis (GSEA) run to 1,000 permutations (30). 
Specifically, we applied the “preranked” GSEA algorithm with default settings and the 
original GSEA implementation of correction for testing multiple pathways using false 
discovery (FDR) and familywise error rates (FWER). The genes in each pathway driving the 
GSEA signal (core genes) were defined as described previously (30). 
Results 
SNP associations 
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An overview of the analytic approaches in this study is provided in Supplementary Figure 1.  
There were 158 and 236 SNPs in analysis of OS in ‘all chemo’ and ‘standard chemo’ 
respectively, and 107 and 252 SNPs in analysis of PFS in ‘all chemo’ and ‘standard chemo’ 
that were above the minimal p-value threshold for suggestive significance (p=1.0x10-5) but 
none reached the nominal level of genome-wide significance (p= 5×10-8; Figure 1).  QQ plots 
and estimates of inflation of the test statistic (λ) revealed some inflation (λ ≤1.15; Supp. 
Figure 2) which could not be accounted for by SNPs with low MAF (<0.1). Manhattan and 
QQ plots for the ‘all OCAC’ OS analysis showed similar effects (Supplementary Figure 3).  
We selected 130 iCOGS SNPs with imputation r2 ≥0.9 and adjusted p≤1.0x10-5 in at least one 
of the four analyses (Supplementary Table 4), and genotyped 48 SNPs at 22 loci in all 
patients with chemotherapy and outcome data. To obtain effect estimates from the largest 
possible sample for PFS and OS in ‘all chemo’ and ‘standard chemo’ for these 48 SNPs, we 
meta-analyzed estimates from iPLEX genotyped samples (n=3,303), iCOGS imputed data on 
non-overlapping samples (n=821), and TCGA data (n=310; Supplementary Table 5). 
Estimates for the most promising SNPs from meta-analysis (p≤1.0x10-5 in at least one of the 
four analyses) are summarized in Table 1.  The strongest association was for rs4910232 at 
11p15.3 and PFS in the ‘all chemo’ analysis (HR=1.17, 95% CI 1.10-1.24; p=4.7x10-7).  The 
Kaplan Meier (KM) plot of genotyped samples for rs4910232 showed a significant trend in 
worse PFS associated with each additional minor allele (Figure 2A) and there was no 
evidence of between-study heterogeneity (p= 0.7, Figure 2B). This SNP lies within the long 
non-coding RNA (lncRNA) RP11-179A10.1.  Two other SNPs, rs2549714 at 16q23 and 
rs6674079 at 1q22 were associated with worse OS in ‘standard chemo’ (p=5.0x10-6) and ‘all 
chemo’ analyses (p=7.1x10-6) respectively, and are also located in lncRNAs (Table 1).  We 
further explored SNPs within a 1Mb region of rs6674079 at the 1q22 locus using ENCODE 
ChiP-Seq data and found that rs6674079 is perfectly correlated with rs11264489 which lies 
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within the super-enhancer MEF2D.  Histone modification tracks from ENCODE for normal 
ovarian cancer cell lines suggest a strong regulatory potential for this SNP (Figure 3).  The 
KM plot for rs6674079 clearly showed a significant per-allele trend in worse OS (Figure 4A) 
and study-specific estimates and heterogeneity tests showed no evidence of between-study 
heterogeneity (p=0.4, Figure 4B).  Forest plots for other significant SNPs (rs7950311, 
rs2549714 and rs3795247) showed an overall trend in worse survival probabilities per minor 
allele (Supplementary Figure 4A-C) and there was no evidence of between-study 
heterogeneity for any of these SNPs (p≥0.14). 
We further queried protein-coding genes within a 1Mb region of each of these lead SNPs at 
1q22, 11p15.4, 11p15.3, 16q23 and 19p12 (Table 1) using KM-plotter to identify gene 
expressions that might be associated with PFS and OS using all available data (1,170 and 
1,435 patients respectively), and in a subset of cases restricted to optimally debulked serous 
cases treated with Taxol and platin chemotherapy (330 and 387 patients respectively).  Of a 
total of 55 expression probes for 174 genes queried across the five loci, significant 
associations that met our Bonferroni-corrected significance threshold of p≤2.3x10-4 were 
observed for 11 probes in at least one analysis (Supplementary Table 6).  The strongest 
association with outcome was observed for PFS and high (defined as above the median) 
expression of SLC25A44 (probe 32091_at) in the unrestricted dataset of 1,170 ovarian cancer 
patients (HR=1.56, 95% CI 1.33-1.82, log-rank p=1.9x10-8; Supplementary Figure 5A).  This 
association was upheld, although more weakly, in the subset restricted to optimally debulked 
serous cases treated with Taxol and platin chemotherapy (n=330, HR=1.66, 95% CI 1.24-
2.23, log-rank p-value=6.8x10-4).  High expression of SEMA4A (probe 219259_at) was 
significantly associated with better PFS in the unrestricted dataset (HR 0.71, 95% CI 0.61 - 
0.82, log-rank p=4.2x10-6; Supplementary Figure 5B) and marginally with OS (unrestricted 
dataset log-rank p=3.3x10-4 and restricted dataset log-rank p=5.7x10-4).  Significantly better 
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PFS was also observed for high expression of SH2D2A (probe 207351_s_at) in the 
unrestricted datasets (HR=0.67, 95% CI 0.57 - 0.77, log-rank p=8.4x10-8; Supplementary 
Figure 5C) with a marginal association for OS in the unrestricted dataset (log-rank p=8.7x10-
4).  
We also evaluated associations between OS and SNPs in the larger ‘all OCAC’ dataset with 
minimal adjustment.  A total of 70 SNPs with imputation r2 ≥0.9 at 4 loci achieved a 
p≤1.0x10-5 (Supplementary Table 7).  The top SNP was rs2013459 (HR=1.14, 95% CI 1.08-
1.20, p= 9.7x10-7 at PARK2 located at 6q26.  Significant SNPs were also identified at FAR1 
(11p15), ANKLE1, BABAM1 and ABHD8 (all at 19p13) and SYNE2 (6q25). 
Pathway Analysis 
We also explored the polygenic signal in our data using pathway-based analysis. This 
enrichment analysis of genome-wide single-variant summary statistics from the ‘standard 
chemo’ subgroup in the context of known biological pathways suggested heterogeneity in the 
pathways that may be associated with PFS and OS. Eight of the 837 pathways tested were 
associated with PFS in the ‘standard chemo’ dataset at nominal significance (pGSEA<0.05 and 
FWERGSEA<1), with the “YAP1- and WWTR1 (TAZ)- stimulated gene expression” 
pathway from the Reactome pathway database emerging as the most significant (pGSEA=1x10-
3, FDRGSEA=0.868, FWERGSEA=0.575, Table 2). Nine of the 837 pathways were associated 
with OS in the ‘standard chemo’ data set at the same threshold for nominal significance and 
the Reactome pathway “HDL-mediated lipid transport” was the top pathway (pGSEA=6x10-3, 
FDRGSEA=0.303, FWERGSEA=0.268, Table 2). Interestingly, the other nominally significant 
pathways suggested possible involvement of cell cycle genes in determining PFS and of 
xenobiotic and insulin metabolism genes in determining OS in the ‘standard chemo’ cohort 
(Table 2). 
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Discussion  
We have evaluated ~2.8 million SNPs across the genome for an association with outcome 
following first-line chemotherapy in a large cohort of EOC patients and identified SNPs at 
five loci with p-values that ranged from 1.05x10-5 to 4.7x10-7.  Three SNPs, rs6674079, 
rs4910232 and rs2549714, were located in long non-coding RNAs (lncRNA) RP11-
284F21.8, RP11-179A10.1 and RP11-314O13.1 respectively (Table 1).  LncRNAs are RNA 
transcripts that have been implicated in a wide range of regulatory functions including 
epigenetic control and regulation of chromatin structure at the cellular level to tumor 
suppressors and regulators of angiogenesis and metastasis (31).  It has been shown that 
alterations in the function of some lncRNAs, particularly those involved in transcriptional 
regulation, can play a critical role in cancer progression and exert its effect on genes located 
on other chromosomes.  A well characterized example of this is the lncRNA HOTAIR which 
has been linked to invasiveness and poor prognosis of breast cancer (32).  HOTAIR is 
expressed from the HOXC gene cluster on chromosome 12, and has been shown to mediate 
repression of transcription of HOXD genes on chromosome 2 via PRC2 (33).  While little is 
known about the specific lncRNAs that we have identified or their target genes, it is likely 
that associated SNPs in these lncRNAs might exert their effects on chromatin modifying 
proteins that regulate genes involved in ovarian cancer progression.  ENCODE ChIP-seq data 
for normal ovarian cell lines at the 1q22 locus shows evidence of histone modification in the 
region of RP11-284F21.8, and rs6674079 at this locus is perfectly correlated with 
rs11264489 which lies within the super-enhancer MEF2D (Figure 4).  Expression studies of 
MEF2D in hepatocellular carcinoma showed that elevated expression promoted cancer cell 
growth and was correlated with poor prognosis in patients (34).  Further analysis of 
rs6674079 and other SNPs identified in this study in lncRNAs would be necessary to 
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determine their putative regulatory effects and potential impact on ovarian cancer metastasis 
and progression. 
Several protein-coding genes within 1Mb of rs6674079 at 1q22 were also found to be 
significantly associated with ovarian cancer progression in unrestricted analyses of KM-
plotter data (Supplementary Table 6).  Above-median expression of SLC25A44 (probe 
32091_at), a recently identified member of the SLC25 family of mitochondrial carrier 
proteins, was significantly associated with worse PFS in analysis in the larger unrestricted 
dataset of epithelial ovarian cancer (log-rank p≤1.9x10-8; Supplementary Figure 4A). While 
relatively little is known about specific functions or disease-gene associations with 
SLC25A44, changes in expression of some members of the SLC25 family of transporters 
have been implicated in resistance to cell death in other cancers (35).  Similarly high 
expression of the signalling protein SEMA4A (probe 219259_at; Supplementary Figure 4B) 
was significantly associated with better PFS (log-rank p=4.2x10-6).  SEMA4A is a member of 
the semaphorin family of soluble and transmembrane proteins which mediate their signal 
transduction effects through plexins, both of which have been shown to have tumorigenic 
properties and are aberrantly expressed in human cancers, (36, 37).  Also high expression of 
SH2D2A (probeset 21925_at) which encodes a T-cell-specific adaptor protein (TSAd), was 
associated with significantly better PFS (log-rank p=8.4x10-8; Supplementary Figure 4C).  
Chromosmal imbalance at 1q22 was previously identified as a candidate region for response 
to chemotherapy in human glioma cell lines (38) and it has been shown that alterations on the 
long arm of chromosome 1, particularly gain of function, are among the most commonly 
reported chromosomal abnormalities in human cancers (39).  Further studies would be 
necessary to delineate the relevance of these novel findings in EOC outcome. 
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 We found that that PFS-associated SNPs in the ‘standard chemo’ dataset were most 
significantly enriched in a pathway containing target genes of the transcriptional co-activators 
YAP1 and WWTR1 and the antisense RNA gene TAZ (40, 41). YAP1, an established ovarian 
cancer oncogene (42), is known to regulate the cell cycle and epithelial-mesenchymal 
transition, promoting tumor survival even in the absence of oncogenic KRAS signaling (43, 
44).  A gene expression signature representing YAP1 activation in ovarian tumors has also 
recently been found to be predictive of response to taxane-based adjuvant chemotherapy 
regimens and is associated with overall survival in ovarian cancer (45).  The HDL-mediated 
lipid transport pathway driven by genes that included APOA1 was associated with OS in the 
setting of standard chemotherapy.  Higher APOA1 expression in serous ovarian cancer 
effusions has previously been associated with improved overall survival in a small cohort 
(46).  Apolipoprotein A-I activity has been shown to reduce viability of platinum-resistant 
human ovarian cancer cells in vitro and inhibit tumor development in a mouse model of 
ovarian cancer (47). 
In our exploratory histology-adjusted analysis of OS in ‘all OCAC’ we observed significant 
associations with SNPs in PARK2 and decreased survival.  PARK2, a component of E3 
ubiquitin ligase complexes that drive cyclin D and E degradation, is frequently lost in human 
cancers, and knock-down in a range of cancer cell lines has been shown to correlate with 
increased cell proliferation and transcription of genes related to cell cycle control, suggesting 
a role in disease progression and prognosis (48).  ANKLE1 and BABAM1 at 19p13.11 
(p≤9.5x10-6 ; Supplementary Table 8) were also identified and SNPs at this locus were 
previously implicated in ovarian cancer risk and survival (49).  However in our fully adjusted 
analysis of ~2900 patients for which we had all covariates, we observed no significant 
association for any SNP at this locus (p≥0.002).  This may be accounted for by the lower 
power to detect the effects seen in the larger ‘all OCAC’ analysis, or the fact that the lower p-
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value in the ‘all OCAC’ analysis is an artefact resulting from partial adjustment for 
confounders of outcome.  Further analyses including FIGO stage, grade and residual disease 
would be necessary to evaluate this locus.  We also observed no significant association for 
candidate SNPs previously identified to be associated with response to chemotherapy using 
the NHGRI GWAS catalog (http://www.genome.gov/gwastudies/ ) with any of our four 
analyses (Supplementary Table 9).  
Our validation analysis of genotyped data also highlighted the potential for spurious 
associations using imputed data in smaller samples sets.  Although current strategies of ‘pre-
phasing’ has improved imputation accuracy for SNPs with MAF 1-3% and prior imputation 
r2 as low as 0.6 in Europeans (50), we observed a high degree of discordance in estimates 
from imputed data compared to actual genotypes, even for SNPs with reasonable imputation 
quality (r2=0.6-0.9) and particularly for SNPs with MAF<3% (Supplementary Methods and 
Supplementary Table 3).  We therefore selected SNPs for validation from ~2.8 million SNPs 
with good imputation quality (r2≥0.9) to reduce the risk of false positives. 
In conclusion we have identified three SNPs in lncRNAs that have not been previously 
reported on that were associated with PFS in ovarian cancer regardless of chemotherapy 
regimens.  We also identified two other SNPs, rs7950311 at 11p15.4 associated with OS in 
the ‘standard chemo’ analysis and rs3795247 at 19p12 associated with PFS in the ‘all chemo’ 
analysis, both of which reside in genes that have not been previously implicated in solid 
tumors.  To our knowledge this is the largest study that comprehensively analyzes genetic 
variation across the genome for an association with ovarian cancer outcomes, both with 
regard to first-line standard-of-care chemotherapy and regardless of treatment.  Since residual 
disease is a strong predictor of overall and progression-free survival, patients were included 
in our main analyses if they received a minimum of cytoreductive surgery and had available 
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information on level of residual disease.  SNPs were prioritized on the basis of good 
imputation quality (r2 ≥0.9) and final estimates were derived from meta-analysis of all 
available data imputed and genotyped samples from OCAC and publicly available TCGA 
data.  To circumvent methodological flaws we restricted the analysis to European invasive 
EOC patients participating in the OCAC with standardized definitions of clinical and 
pathological characteristics.  Despite our rigorous analysis approach, there are inherent 
limitations in the observational design of our study that a randomized clinical trial would 
circumvent, in that standardized treatment and outcome measurements would be available, 
and the presence of a control group receiving an alternative treatment would allow 
assessment of a likely causal relationship between the putative associations and treatment 
modalities. 
Pharmacogenomic studies hold the promise of improving treatment approaches by the 
identification of genetic markers which may enhance the clinical approaches and cost-
effectiveness of these treatment approaches.  However, large clinical trials or well-designed 
prospective cohort studies that take into account differential responses according to EOC 
tumor types, as well as functional studies that shed light on putative associations are required 
to succeed in defining the role of genetics in ovarian cancer progression and survival. 
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Gynaecologic Disease (WMH) thank the Gynaecological Oncology Biobank at Westmead, a 
member of the Australasian Biospecimen Network-Oncology group, which is funded by the 
National Health and Medical Research Council Enabling Grants ID 310670 & ID 628903 and 
the Cancer Institute NSW. 
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Table 1:  Results of meta-analysis of estimates from iPLEX genotyped, non-overlapping iCOGS and TCGA datasets for selected promising 
SNPs 
 
            OVERALL SURVIVAL PROGRESSION-FREE SURVIVAL 
            All Chemo (N=4,426) Standard Chemo (N=1,799) All Chemo (N=4,095) 
Standard Chemo 
(N=1,598) 
SNP Chr Position Nearest Gene 
Effect/
Ref 
Allele 
aEffect 
Allele 
Freq. bHR (95% CI) P bHR (95% CI) P bHR (95% CI) P bHR (95% CI) P 
rs6674079 1q22 156486061 RP11-284F21.8 G/A 0.28 1.15 (1.08 -1.23) 7.1x10-6 1.07 (0.97-1.18) 1.9x10-1 1.07 (1.01-1.13) 2.8x10-2 0.98 (0.90-1.07) 6.8x10-1 
rs7950311 11p15.4 5672354 HBG2 C/T 0.48 1.10 (1.04-1.17) 1.7x10-3 1.28 (1.16-1.42) 6.8x10-7 1.03 (0.98-1.09) 2.5 x10-1 1.08 (0.99-1.18) 7.8x10-2 
rs4910232 11p15.3 11120369 RP11-179A10.1 G/T 0.32 1.12 (1.05-1.19) 9.4x10-4 1.20 (1.08-1.33) 5.3x10-4 1.17 (1.10-1.24) 4.7x10-7 1.24 (1.12-1.56) 1.2x10-5 
rs2549714 16q23 80875263 RP11-314O13.1 C/A 0.06 1.20 (1.06-1.36) 3.4x10-3 1.53 (1.28-1.84) 5.0x10-6 1.14 (1.01-1.28) 2.8 x10-2 1.29 (1.08-1.55) 5.6x10-3 
rs3795247 19p12 21906428 ZNF100 C/T 0.08 1.16 (1.04-1.30) 8.8x10-3 1.34 (1.13-1.60) 9.7x10-4 1.26 (1.14-1.40) 1.05x10-5 1.39 (1.18-1.65) 9.2x10-5 
a Effect allele frequency from genotyped samples 
b Estimates are adjusted for residual disease (nil vs. any), FIGO stage (I-IV), tumor histology (serous, mucinous, endometrioid, clear cell, other epithelial), grade (low vs. 
high), site, age at diagnosis (OS only) and the first 3 principal components (imputed data only). BAV & NCO included only in OS analysis. 
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Table 2: Gene set enrichment (pathway-level) analysis results for PFS and OS associations in the 'standard chemo' data set 
 
Pathway aGenes p-value bFDR cFWER Core genes 
Pathways associated with PFS in 'standard chemo' at p<0.05 and FWER<1 
REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRE
SSION 
23 0.001 0.868 0.575 CTGF,TBL1X,NCOA6,TEAD3,MED1,PPARA,TEAD1,NCOA3,
KAT2B 
REACTOME_G0_AND_EARLY_G1 23 0.012 1 0.991 RBL2,CDC25A,MYBL2,LIN9,HDAC1,CCNA1,LIN52 
REACTOME_AMINE_DERIVED_HORMONES 15 0.025 1 0.993 CGA,TPO,SLC5A5,TH 
REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER 21 0.010 1 0.994 ERCC2,RAD23B,GTF2H1,GTF2H2,RPA1,ERCC1,DDB2,XPA,
DDB1 
REACTOME_G_PROTEIN_ACTIVATION 27 0.007 1 0.999 GNB2,GNAT1,GNAI2,GNAI1,POMC,GNB3,GNG4,GNGT2,GN
AO1,GNG8,GNG3 
REACTOME_LYSOSOME_VESICLE_BIOGENESIS 22 0.013 1 0.999 CLTA,AP1B1,AP1S1,DNAJC6,AP1G1,GNS,M6PR,VAMP8,BL
OC1S1 
REACTOME_INHIBITION_OF_INSULIN_SECRETION_BY_ADRENALI
NE_NORADRENALINE 
25 0.014 1 0.999 GNB2,GNAI2,CACNB2,GNAI1,ADRA2A,GNB3,GNG4,GNGT2
,GNAO1,GNG8,GNG3 
REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_DURING_G2_M_
TRANSITION 
15 0.025 1 0.999 CDC25A,PLK1,CCNA1,WEE1,CDC25B,PKMYT1,XPO1 
Pathways associated with OS in 'standard chemo' at p<0.05 and FWER<1 
REACTOME_HDL_MEDIATED_LIPID_TRANSPORT 15 0.006 0.303 0.268 BMP1,CETP,APOA1,APOC3,ABCG1 
REACTOME_XENOBIOTICS 15 0.009 1 0.891 CYP2A13,CYP2B6,CYP2F1 
REACTOME_LIPOPROTEIN_METABOLISM 28 0.005 1 0.979 BMP1,CETP,APOA1,APOC3,APOA5,ABCG1 
REACTOME_INSULIN_SYNTHESIS_AND_PROCESSING 20 0.005 0.915 0.980 SNAP25,INS,EXOC5,ERO1L,PCSK1,EXOC4,PCSK2 
BIOCARTA_MTA3_PATHWAY 19 0.013 0.772 0.982 TUBA1A,TUBA1C,HDAC1,MBD3,ALDOA,CDH1,MTA1,SNAI
2,TUBA3C 
REACTOME_ACETYLCHOLINE_BINDING_AND_DOWNSTREAM_EV
ENTS 
15 0.022 0.781 0.994 CHRNG,CHRND 
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_7
ALPHA_HYDROXYCHOLESTEROL 
15 0.032 0.716 0.996 SLC27A5, HSD17B4, AKR1D1, SLC27A2, CYP27A1, ACOX2, 
HSD3B7, ABCB11 
KEGG_MATURITY_ONSET_DIABETES_OF_THE_YOUNG 23 0.006 0.658 0.997 ONECUT1, INS, HNF1A, BHLHA15, NR5A2, FOXA3 
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A
_LYMPHOID_AND_A_NON_LYMPHOID_CELL 
56 0.001 0.621 0.998 CD96, CD8A, CD8B, IFITM1, KIR3DL2, CRTAM, ICAM2, 
KIR3DL1, FCGR3A, LILRB2, CD19, LILRB5, LILRB3, 
CD200R1, RAET1E, FCGR2B, SELL,ULBP2, ULBP1, 
KIR2DL4, B2M, CDH1, CD81 
aNumber of genes; bFalse Discovery Rate; cFamilywise Error Rates 
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Figure Legends 
 
 
Figure 1: Manhattan plots of ~2.8 million SNPs in four analyses of the cohort selected 
for first-line chemotherapy.  SNPs with MAF ≥0.02 and imputation r2 ≥0.9 associated with 
Overall Survival in A. ‘All Chemo’ and B. ‘Standard chemo’, and Progression-free survival 
in C. ‘All chemo’ and D. ‘Standard chemo’; the blue line represents suggestive significance 
(p=1x10-5) and the red line represents genome wide significance (p=5x10-8). 
 
Figure 2:  Progression-free survival in ‘all chemo’ analysis for rs4910232.  A. Kaplan 
Meier curve for PFS in ‘all chemo’ dataset (n=3,177); P-values derived from adjusted Cox 
PH models of genotyped samples; 0=common homozygotes AA, 1=heterozygotes AG, 
2=rare homozygotes GG.  B. Forest plot showing site-specific estimates for PFS and 
rs4910232 in ‘all chemo’ dataset.   
 
Figure 3: ENCODE ChIP-seq data at 1q22 locus. Manhattan plot of all iCOGS 
imputed/genotyped SNPs at 1q22, black enclosed circles represent genotyped SNPs while 
open red circles are imputed SNPs.  Hash marks indicate location of highly correlated SNPs 
(r2 >0.9).  Colored histograms denote histone modification for H3K4me1 and H3K27ac in 
normal ovary ChIP-seq data from UCSD and ENCODE. 
 
Figure 4: Overall survival in ‘all chemo’ for rs6674079.  A. Kaplan Meier curve for OS in 
the ‘all chemo’ dataset.  P-value derived from adjusted Cox PH models of genotyped samples 
(n=4,399): 0=common homozygotes AA, 1=heterozygotes AG, 2=rare homozygotes GG.  B. 
Forest plot showing site-specific estimates for OS and rs6674079 in ‘all chemo’ dataset 
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A. B. 
C. D. 
Figure 1:  Manhattan plots of ~2.8 million SNPs (imputation r2 ≥0.9) in four analyses of cohorts 
selected according to first-line chemotherapy.  
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Figure 2A:  PFS in ‘all chemo’ analysis for rs4910232.  Kaplan Meier curve for PFS in ‘all chemo’ 
dataset (n=3,177); P-values derived from adjusted Cox PH models of genotyped samples; 0=common 
homozygotes AA, 1=heterozygotes AG, 2=rare homozygotes GG  
adjusted P= 1.84E-06 
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Figure 2B:  Forest plot showing site-specific estimates for PFS and rs4910232 in ‘all 
chemo’ dataset 
Research. 
on October 12, 2015. © 2015 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 7, 2015; DOI: 10.1158/1078-0432.CCR-15-0632 
Figure 3: ENCODE ChIP-seq data at 1q22 locus. Black enclosed circles represent genotyped SNPs 
while open red circles are imputed SNPs.  Hash marks indicate location of highly correlated SNPs (r2 >0.9).  
Colored histograms denote histone modification for H3K4me1 and H3K27ac in normal ovary ChIP-seq data from 
UCSD and ENCODE. 
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Figure 4A:  OS in ‘all chemo’ analysis for rs6674079. P-value derived from adjusted Cox PH 
models of genotyped samples (n=4,399); 0=common homozygotes AA, 1=heterozygotes AG, 2=rare 
homozygotes GG.   
adjusted (genotyped) P=7.10E-06 
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Figure 4B:  Forest plot showing site-specific estimates for OS and rs6674079 in the ‘all 
chemo’ dataset. 
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